Abstract
BackgroundIxekizumab (IXE), an Interleukin (IL)-17A inhibitor (i), approved for the treatment (tx) of Psoriasis (Pso), psoriatic arthritis (PsA) and axSpA (rad/non rad) have limited real-world data. PRO-SPIRIT is the first...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
